Methyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis manner

Abstract Background Bladder cancer (BC) is a malignant tumor. Methyltransferase-like 7B (MEETL7B) is a methyltransferase and its role in BC has not yet been revealed. Method Stable METTL7B knockdown or overexpression were achieved by lentiviral transduction in SW780 and TCCSUP cell lines. Xenografts...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiani He, Changming Dong, Xiandong Song, Zhongkai Qiu, Hao Zhang, Yuanjun Jiang, Tao Liu, Xiaojun Man
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Biology Direct
Subjects:
Online Access:https://doi.org/10.1186/s13062-025-00597-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585999545270272
author Jiani He
Changming Dong
Xiandong Song
Zhongkai Qiu
Hao Zhang
Yuanjun Jiang
Tao Liu
Xiaojun Man
author_facet Jiani He
Changming Dong
Xiandong Song
Zhongkai Qiu
Hao Zhang
Yuanjun Jiang
Tao Liu
Xiaojun Man
author_sort Jiani He
collection DOAJ
description Abstract Background Bladder cancer (BC) is a malignant tumor. Methyltransferase-like 7B (MEETL7B) is a methyltransferase and its role in BC has not yet been revealed. Method Stable METTL7B knockdown or overexpression were achieved by lentiviral transduction in SW780 and TCCSUP cell lines. Xenografts tumors were established via subcutaneous injection of stable transfectants in BALB/c mice. Results A database search indicated that METTL7B was elevated in BC and it was validated in BC cell lines. METTL7B silencing suppressed cell proliferation and tumorigenesis in vitro and in vivo. Besides, METTL7B knockdown induced cell cycle arrest in G1 phase with a reduction in cyclin D1(CCND1), CDK4, and CDK6 levels and an elevation in CDKN2D levels in cells. Considering that ferroptosis is emerging as a therapeutic target for cancer, and the possible relationship between METTL7B and antioxidant enzymes. We, here, examined that ectopic METTL7B expression abolished ferroptosis markers in cells raised by Erastin treatment, including the production of lipid ROS, the increased cellular iron and MDA content, the decreased gene expression of ACSL3, FANCD2, and FADS2, as well as the mitochondrial injury observed by electron microscopy. Mechanically, ectopic METTL7B expression promoted m6A modification on ACSL3 mRNA. Gain of functional experiment exhibited that METTL7B inhibited Erastin-induced ferroptosis via ACSL3. Overexpressed PLAGL2 is identified as a possible independent predictor in BC and bioinformatics predicted the potential binding sites between PLAGL2 and METTL7B promoter region. Dual luciferase and chromatin immunoprecipitation analysis provided evidence that PLAGL2 directly binds to METTL7B promoter region. Conclusions METTL7B is involved in BC development and progression. METTL7B may mediate m6A modification on ACSL3 mRNA to negatively regulate ferroptosis in BC cells, which provides a potential therapeutic target for BC via ferroptosis. Graphical Abstract
format Article
id doaj-art-84bfa23747754bf09862d839fbcb1c96
institution Kabale University
issn 1745-6150
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series Biology Direct
spelling doaj-art-84bfa23747754bf09862d839fbcb1c962025-01-26T12:19:26ZengBMCBiology Direct1745-61502025-01-0120111510.1186/s13062-025-00597-zMethyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis mannerJiani He0Changming Dong1Xiandong Song2Zhongkai Qiu3Hao Zhang4Yuanjun Jiang5Tao Liu6Xiaojun Man7Department of Surgical Oncology and Breast Surgery, The First Hospital of China Medical UniversityDepartment of Urology, The First Hospital of China Medical UniversityDepartment of Urology, The First Hospital of China Medical UniversityInstitute of Urology, Benxi Central HospitalDepartment of Urology, The First Hospital of China Medical UniversityDepartment of Urology, The First Hospital of China Medical UniversityDepartment of Urology, The First Hospital of China Medical UniversityDepartment of Urology, The First Hospital of China Medical UniversityAbstract Background Bladder cancer (BC) is a malignant tumor. Methyltransferase-like 7B (MEETL7B) is a methyltransferase and its role in BC has not yet been revealed. Method Stable METTL7B knockdown or overexpression were achieved by lentiviral transduction in SW780 and TCCSUP cell lines. Xenografts tumors were established via subcutaneous injection of stable transfectants in BALB/c mice. Results A database search indicated that METTL7B was elevated in BC and it was validated in BC cell lines. METTL7B silencing suppressed cell proliferation and tumorigenesis in vitro and in vivo. Besides, METTL7B knockdown induced cell cycle arrest in G1 phase with a reduction in cyclin D1(CCND1), CDK4, and CDK6 levels and an elevation in CDKN2D levels in cells. Considering that ferroptosis is emerging as a therapeutic target for cancer, and the possible relationship between METTL7B and antioxidant enzymes. We, here, examined that ectopic METTL7B expression abolished ferroptosis markers in cells raised by Erastin treatment, including the production of lipid ROS, the increased cellular iron and MDA content, the decreased gene expression of ACSL3, FANCD2, and FADS2, as well as the mitochondrial injury observed by electron microscopy. Mechanically, ectopic METTL7B expression promoted m6A modification on ACSL3 mRNA. Gain of functional experiment exhibited that METTL7B inhibited Erastin-induced ferroptosis via ACSL3. Overexpressed PLAGL2 is identified as a possible independent predictor in BC and bioinformatics predicted the potential binding sites between PLAGL2 and METTL7B promoter region. Dual luciferase and chromatin immunoprecipitation analysis provided evidence that PLAGL2 directly binds to METTL7B promoter region. Conclusions METTL7B is involved in BC development and progression. METTL7B may mediate m6A modification on ACSL3 mRNA to negatively regulate ferroptosis in BC cells, which provides a potential therapeutic target for BC via ferroptosis. Graphical Abstracthttps://doi.org/10.1186/s13062-025-00597-zBladder cancerMETTL7Bm6A modificationACSL3Ferroptosis
spellingShingle Jiani He
Changming Dong
Xiandong Song
Zhongkai Qiu
Hao Zhang
Yuanjun Jiang
Tao Liu
Xiaojun Man
Methyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis manner
Biology Direct
Bladder cancer
METTL7B
m6A modification
ACSL3
Ferroptosis
title Methyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis manner
title_full Methyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis manner
title_fullStr Methyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis manner
title_full_unstemmed Methyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis manner
title_short Methyltransferase-like 7B participates in bladder cancer via ACSL3 m6A modification in a ferroptosis manner
title_sort methyltransferase like 7b participates in bladder cancer via acsl3 m6a modification in a ferroptosis manner
topic Bladder cancer
METTL7B
m6A modification
ACSL3
Ferroptosis
url https://doi.org/10.1186/s13062-025-00597-z
work_keys_str_mv AT jianihe methyltransferaselike7bparticipatesinbladdercancerviaacsl3m6amodificationinaferroptosismanner
AT changmingdong methyltransferaselike7bparticipatesinbladdercancerviaacsl3m6amodificationinaferroptosismanner
AT xiandongsong methyltransferaselike7bparticipatesinbladdercancerviaacsl3m6amodificationinaferroptosismanner
AT zhongkaiqiu methyltransferaselike7bparticipatesinbladdercancerviaacsl3m6amodificationinaferroptosismanner
AT haozhang methyltransferaselike7bparticipatesinbladdercancerviaacsl3m6amodificationinaferroptosismanner
AT yuanjunjiang methyltransferaselike7bparticipatesinbladdercancerviaacsl3m6amodificationinaferroptosismanner
AT taoliu methyltransferaselike7bparticipatesinbladdercancerviaacsl3m6amodificationinaferroptosismanner
AT xiaojunman methyltransferaselike7bparticipatesinbladdercancerviaacsl3m6amodificationinaferroptosismanner